Viewing data from:

BENZONATATE

ANDA

BENZONATATE | A040587 | SUN PHARMACEUTICAL INDUSTRIES INC

2 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Benzonatate (2023)

Total Spending

$1.5M

Total Claims

133,974

Beneficiaries

92,427

Avg Cost/Unit

$0.37

Spending Trend

$382K(2019)→$564K(2020)→$626K(2021)→$1.2M(2022)→$1.5M(2023)

YoY Change:-8.0%

5yr CAGR:+1.8%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain4 active DMFs1 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

W R GRACE AND CO -CONNBENZONATATE USP

DMF 51961983

SIEGFRIED EVIONNAZ SABENZONATATE

DMF 78431988

FORMOSA LABORATORIES INCBENZONATATE USP

DMF 217032008

AMI LIFESCIENCES PRIVATE LTDBENZONATATE

DMF 390022023

KINGLAND CHEMICALS CO LTDInactiveBENZONATATE

DMF 241942010

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — 100MG

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Mar 19, 2008

No patent or exclusivity listings for this strength.

#002 — 200MG

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Mar 19, 2008